A Phase II Study of Bortezomib (VelcadeÂ, PS-341) and Docetaxel for Patients With Hormone Refractory Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 21 May 2018
At a glance
- Drugs Bortezomib (Primary) ; Docetaxel
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Aug 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.
- 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.